Journal
VACCINES
Volume 10, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/vaccines10122063
Keywords
SARS-CoV-2; neutralizing antibodies; severity; variants
Categories
Ask authors/readers for more resources
The study aims to characterize the primary humoral immune host response in the early stages of SARS-CoV-2 infection and investigate its association with neutralizing antibodies, antibody levels, viral lineage, and clinical outcomes. The results suggest that developing an early and robust neutralizing response may increase survival probability in critical patients.
The host immune response to SARS-CoV-2 appears to play a critical role in disease pathogenesis and clinical manifestations in severe COVID-19 cases. Until now, the importance of developing a neutralizing antibody response in the acute phase and its relationship with progression to severe disease or fatal outcome among hospitalized patients remains unclear. In this study, we aim to characterize and compare longitudinally the primary humoral immune host response in the early stages of the disease, looking for an association between neutralization, antibody titers, infective viral lineage, and the clinical outcome in hospitalized and non-hospitalized patients. A total of 111 patients admitted at INER from November 2021 to June 2022 were included. We found that patients with negative or low neutralization showed a significant reduction in survival probability compared to patients with medium or high neutralization. We observed a significant decrease in the median of neutralization in patients infected with viral variants with changes in RBD of the spike protein. Our results suggest that developing an early and robust neutralizing response against SARS-CoV-2 may increase survival probability in critical patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available